Better Education on Glomerular Disease: Improving Diagnosis and Treatment of C3 Glomerulopathy

To participate in this activity, please:

Nephrology specialists Carla Nester, MD, and Andrew Bomback, MD, delve into the rare and difficult-to-diagnose disease state of C3 glomerulopathy, a membranoproliferative form of glomerulonephritis. Recent guideline updates and recommended clinical management strategies for the treatment of glomerular disease are reviewed. In addition, the specific pathophysiology, clinical features and diagnosis of C3 glomerulopathy are discussed, as well as the global patient burden of disease and concomitant disease states caused by complement dysregulation. Insight into the historical management of C3 glomerulopathy and targeted therapies currently undergoing evaluation in late clinical trials are provided. Finally, patient resources, supportive measures and clinical perspective on the future of C3 glomerulopathy management are discussed by the faculty.

This program is also available as a podcast. You may download it here:

Course Credit:

1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
1 Pharmacology Hour


Opens: 2022-12-15
Closes: 2023-12-15

Target Audience:

This activity is intended for nephrologists, nephrology physician associates/physician assistants and nurse practitioners, primary care physicians, pediatricians, surgeons who specialize in organ transplants, and other healthcare professionals who may be involved in diagnosis and treatment of patients with C3 glomerulopathy (C3G).

This activity is supported by an educational grant from Novartis.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 contact hour, including 1 pharmacology hour.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Heather Jimenez, MSN, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Laura Schmidt, PharmD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Andrew S. Bomback, MD, MPH

    Associate Professor of Medicine
    Director of Clinical Research, Division of Nephrology
    Columbia University Irving Medical Center
    New York, New York

  • Carla M. Nester, MD, MSA

    Jean E. Robillard MD Endowed Chair in Pediatric Nephrology
    Director, Division of Pediatric Nephrology, Dialysis and Transplantation
    Associate Director, Molecular Otolaryngology and Renal Research Laboratory
    University of Iowa Stead Family Children’s Hospital
    Iowa City, Iowa

Learning Objectives

  • Discuss recent guideline recommendations on glomerular disease management
  • Describe the epidemiology and pathophysiology of C3G
  • Identify the appropriate imaging and testing for diagnosis of C3G
  • Construct treatment plans for patients diagnosed with C3G
  • Describe the safety and efficacy of targeted therapies undergoing late-phase clinical trial evaluation in patients with C3G

Faculty Disclosures

Andrew S. Bomback, MD, MPH

Consultant: Achillion, Alexion, Apellis, Catalyst, ChemoCentryx, Novartis, Silence, Visterra, Q32

Carla M. Nester, MD, MSA

Advisory Board: Apellis, BioCryst, Novartis

Data Monitoring Safety Board: Kira

Research Support: Apellis, BioCryst, ChemoCentryx, Novartis, Retrophin